Abstract Purpose: ErbB receptor signaling pathways are important regulators of cell fate, and their dysregulation, through (epi)genetic alterations, plays an etiologic role in multiple cancers. ErbB ligands are synthesized as membrane-bound precursors that are cleaved by members of the ADAM family of zinc-dependent metalloproteases. This processing, termed ectodomain shedding, is essential for the functional activation of ErbB ligands. Recent studies suggest that elevated levels of ErbB ligands may circumvent the effectiveness of ErbB-targeted therapeutics. Here, we describe the discovery and preclinical development of potent, selective inhibitors of ErbB ligand shedding. Experimental Design: A series of biochemical and cell-based assays were established to identify selective inhibitors of ErbB ligand shedding. The therapeutic potential of these compounds was assessed in multiple in vivo models of cancer and matrix metalloproteaser elated toxicity. Results: INCB3619 was identified as a representative selective, potent, orally bioavailable small-molecule inhibitor of a subset of ADAM proteases that block shedding of ErbB ligands. Administration of INCB3619 to tumor-bearing mice reduced ErbB ligand shedding in vivo and inhibited ErbB pathway signaling (e.g., phosphorylation of Akt), tumor cell proliferation, and survival. Further, INCB3619 synergized with clinically relevant cancer therapeutics and showed no overt or compounding toxicities, including fibroplasia, the dose-limiting toxicity associated with broad-spectrum matrix metalloprotease inhibitors. Conclusions: Inhibition of ErbB ligand shedding offers a potentially novel and well-tolerated therapeutic strategy for the treatment of human cancers and is currently being evaluated in the clinic.
The ErbB family is composed of four members, epidermal growth factor (EGF) receptor (EGFR; HER1 or ErbB1), HER2 (neu or ErbB2), HER3 (ErbB3), and HER4 (ErbB4). Eleven ligands have been reported to bind to EGFR, HER3, and HER4 and show some level of receptor selectivity (1) . HER2 has no confirmed extracellular ligand and serves as the preferred dimerization partner for other ErbB receptors (2) . Ligand binding results in receptor dimerization, kinase domain activation (except for HER3 which lacks a functional kinase active site), receptor phosphorylation, and the activation of multiple downstream signaling cascades with pleiotropic oncogenic effects when dysregulated-a common event in cancer (3 -5) . Accordingly, the ErbB family represents a validated therapeutic target for the treatment of cancer and has resulted in the development of multiple therapeutics, including the antibodies trastuzumab (directed against HER2) and cetuximab (directed against EGFR) as well as low molecular weight, ATP-competitive tyrosine kinase inhibitors (TKI) targeting EGFR-gefitinib and erlotinib (reviewed in ref. 5 ). Although such targeted therapeutics have shown dramatic antitumor effects in a subset of patients, many do not respond and most eventually become resistant.
Despite the fact that certain tumor traits have been identified that may be associated with clinical responses to EGFR TKIs (e.g., EGFR gene amplification or a subset of somatic mutations in exons 18 to 21, or mesenchymal characteristics), they can account for only a fraction of those patients achieving clinical benefit from treatment. Substantial preclinical and clinical evidence exist, suggesting that the different ErbB pathways may compensate for one another, thus providing a mechanism of resistance against an agent targeting an individual pathway. For instance, increased levels of the EGFR ligand transforming growth factor-a (TGF-a) have been observed in trastuzumabtreated breast cancer patients with progressive disease (6) . Similar results were obtained in a preclinical model of trastuzumab resistance that showed a concordant increased sensitivity to an EGFR-selective TKI (7) . Moreover, a nonbiased analysis of patients receiving gefitinib described significantly elevated expression of the ErbB ligands amphiregulin and TGFa in nonresponders, agreeing with in vitro data suggesting that high ErbB ligand concentrations can circumvent the effectiveness of an EGFR-targeted agent (8, 9) 3 or the less selective ErbB kinase inhibitor GW572016 (10) . These data are consistent with the preclinical observation that targeting the EGFR pathway at multiple points (ligand binding and ATP pocket) may be more efficacious than either method in isolation (11, 12 )-a hypothesis currently being evaluated clinically. Finally, even in patients who do respond to EGFR-selective TKIs, the emergence of secondary mutations in the EGFR kinase domain affords resistance to the ATP-competitive TKIs (13 -16) . Although this is an evolving field, these and other data support the following concepts: (a) although ErbBtargeted agents have shown clinical promise, there is significant room for improvement; (b) a multifaceted approach to inhibiting multiple ErbB pathways would be expected to improve therapeutic response; and (c) inhibiting the activation of multiple ErbB ligands represents a logical and perhaps clinically relevant point of intervention.
Although certain broad spectrum matrix metalloprotease (MMP) inhibitors (e.g., marimastat) can inhibit EGFR ligand shedding in vitro (among other activities), this has not been investigated in vivo nor has the therapeutic hypothesis been tested clinically due to the lesser potency of these drugs against key ADAM protease-relative to MMPs (see below)-and their inability to be tolerated at higher doses (17) . Here, we describe the discovery and preclinical development of selective inhibitors of ErbB ligand shedding and show that these compounds inhibit ErbB ligand shedding and tumor growth in vivo without inducing joint fibroplasias, the dose-limiting toxicity of many MMP inhibitors. These compounds possess the pharmacologic properties making them ideal candidates to test the therapeutic potential of sheddase inhibition for the treatment of cancer in a clinical setting.
Materials and Methods
In vitro metalloprotease and pharmacology assays. Sheddase inhibitors were synthesized at Incyte Corp as described (18) . 4 Human MMPs, ADAM9, and ADAM10 were purchased from R&D Systems (Minneapolis, MN) and assayed as recommended by the manufacturer. The peptide substrate (7-methoxycoumarin-4-yl) acetyl-Pro-Leu-Gly-Leu-(3-[2,4-dinitrophenyl]-L-2, 3-diaminopropionyl)-Ala-Arg-NH2 was used for the MMP assays as recommended by the manufacturer (R&D Systems). Partially purified porcine ADAM17 was obtained from spleen as described (19) . The fluorogenic peptide substrate, (7-methoxycourmarin-4-yl)-acetyl-Pro-Leu-Ala-Gln-Ala-Val-(3-[2,4-dinitrophenyl]-L-2, 3-diaminopropionyl)-Arg-Ser-Ser-Ser-Arg-NH 2 , was used for the AD-AM9, ADAM10, and ADAM17 assays following the manufacturer's recommendations (R&D Systems). INCB3619 was also screened against a panel of G-protein coupled receptors and ion channels for inhibitory activity (ExpresSProfile, Cerep, Inc., Paris, France).
Cell culture and generation of stable cell lines. Cell lines were obtained from American Type Culture Collection (Manassas, VA) and were cultured as recommended by the supplier. Retroviral transduction was used to generate derivatives of the NMuMG and Rat-1 cells as described previously (20) . The coding region of the human cDNA for TGF-a was cloned into pMSCVpuro (BD Biosciences, Mountain View, CA) following amplification from a pool of human cDNA (BD QUICKClone). Human umbilical vascular endothelial cells were obtained from Cambrex Corp (East Rutherford, NJ) and treated following the manufacturer's protocols.
Analysis of ErbB ligand shedding and its effect. The TGF-a cleavage assay used SCC9 cells stimulated with 10 Amol/L phorbol 12-myristate 13-acetate (Sigma-Aldrich, St. Louis, MO) for 30 min in serumfree medium following a 30-min pretreatment with DMSO or metalloprotease inhibitor. Supernatants were collected and assayed for soluble TGF-a by a commercially available ELISA kit (R&D Systems). Alternatively, NMuMG or Rat-1 cells were grown for 24 h in the presence of DMSO or sheddase inhibitor, and supernatants were analyzed in a similar manner. Amphiregulin release was measured in supernatants of HCT116 stimulated with phorbol 12-myristate 13-acetate (1 Amol/L, 30 min) using an ELISA kit (R&D Systems). The heparin-binding EGF-like growth factor (HB-EGF) cleavage assay used Chinese hamster ovary cells stably transfected with human placental alkaline phosphatase -tagged HB-EGF (In Vitro Biology Department of Incyte Corporation, Wilmington, DE). The transfected Chinese hamster ovary cells were grown in 96-well plates and treated with DMSO or compound for 10 min followed by phorbol 12-myristate 13-acetate stimulation (2 Amol/L, 45 min). Alkaline phosphatase activity was assessed using a luminescent substrate (Roche Molecular Biochemicals, Indianapolis, IN). Heregulin cleavage was assessed using Chinese hamster ovary-K1 cells transiently transfected with the human heregulin-h1 cDNA in pCDNA3.2-DESTTM (In Vitro Biology Department of Incyte Corporation) using Lipofect-AMINE 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Following transfection, the cells were grown in serumfree medium for 24 h. Cells were pretreated with DMSO or compound for 15 min and stimulated with phorbol 12-myristate 13-acetate (1 Amol/L, 60 min). Heregulin-h1 was quantified in the supernatants using a commercially available human NRG1-h1/HRG1-h1 ELISA kit (R&D Systems) according to the manufacturer's instructions.
Conditioned medium experiments used NMuMG-T cells grown in the presence of DMSO or INCB3619 for 24 h. Medium was collected and concentrated (Amicon Centriplus, Millipore Corp., Billerica, MA) and applied to serum-deprived (6 h) A431 cells for 30 min. Protein extracts were then subjected to immunoblotting using antibodies against total EGFR and phosphorylated EGFR (Tyr 1173 ) antibodies (Cell Signaling, Beverly, MA).
Primary head and neck cancer cells were obtained from a consenting patient with squamous cell carcinoma of the buccal mucosa (approved by the University of Pittsburgh Institutional Review Board). The patient was not previously treated with standard therapies. Cells were maintained in DMEM, 10% fetal bovine serum, and 2 mmol/L glutamine, and passed 1:10 weekly. Epithelial cells were separated from fibroblasts using selective trypsinization. For proliferation assays, cells were seeded at 10 3 per well in the in a 96-well plate and allowed to attach overnight. The medium was then replaced with 100 AL of low serum medium (2% fetal bovine serum) containing compound or DMSO and maintained for 5 days. Viability was assessed following manufacturer's protocols (Promega Cell-Titer Glo, Madison, WI) and percentage inhibition of growth was determined relative to the DMSO control. Amphiregulin shedding was determined from 4 Â 10 5 cells per well in 12-well plates, which were allowed to attach overnight. The medium was replaced with low serum medium (2% fetal bovine serum) -containing compound or DMSO and incubated overnight. Centrifuged medium was collected and analyzed following manufacturer's protocols by ELISA (R&D Systems-Human Amphiregulin Duoset). Percentage inhibition was calculated relative to a DMSO control.
Animal studies. Animal studies were done under Animal Welfare Regulation Guidelines in a facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care. BALB/c or CD-1 nu/nu mice (Charles River, Wilmington, MA) were injected s.c. with logarithmically growing cells suspended in either serum-free culture medium, or a 1:1 mixture medium and Matrigel (BD Biosciences). The MCF-7 tumor model required implantation of estradiol pellets (17-h estradiol, 0.72 mg/pellet, 60-day release; Innovative Research of America, Sarasota, FL). NMuMG-T tumors were implanted as s.c. tumor fragments (2 Â 2 mm). Tumor size was followed using a caliper to measure the length (l) and width (w) of tumors to calculate an approximate volume [(l Â w 2 ) / 2]. In efficacy studies, treatment was usually initiated when mean tumor volumes were f150 mm 3 , whereas in some pharmacodynamic marker studies, tumors were twice to thrice larger at the time of treatment. Tumor growth delay represents the difference in time for the treated group (T) and a control group (C) to reach a predetermined mean tumor size and was calculated for long-term studies (TGD = T À C). Alternatively, tumor growth inhibition (TGI) was calculated throughout the experiment [TGI = (1 À T / C) Â 100]. S.c. implantation of osmotic pumps (Alzet, Cupertino, CA) was done under isofluorane anesthesia following manufacturer's protocol. These pumps were used to administer INCB3619 or marimastat in all animal studies.
Determination of circulating TGF-a levels in mice was done in immunocompromised mice bearing s.c. well-established Rat-1-T tumors (>200 mm 3 ). Briefly, tumor-bearing animals were randomized into two groups with similar mean tumor volumes. Plasma was then collected via retro-orbital bleeding 2 days after implantation of s.c. Alzet pumps delivering vehicle or INCB3619 (120 mg/kg/d). TGF-a levels were determined from plasma samples in similar fashion as described above.
The murine fibroplasia model was adapted from Renkiewicz et al. (21) . Synovial fibroplasias was scored on a scale of 0 (no change) to 3 [severe collagen deposition and fibroblast proliferation resulting in an increase (>10-fold) in the ratio of synovium to subsynovial tissue mass].
Hematology and clinical chemistry analyses were done by DuPont Haskell Laboratories (Newark, DE).
Evaluation of compound levels in plasma was done using standard liquid chromatography-tandem mass spectrometry techniques.
Ex vivo analysis of tumor material. Tissues were fixed in 10% neutral buffered formalin for at least 24 h at room temperature before standard processing and treatment with 3% H 2 O 2 for 15 min to quench any endogenous peroxidase activity. Preheated citrate buffer (Antigen Unmasking Solution, Vector Laboratories, Burlingame, CA) was used for antigen retrieval and background staining was reduced using the Avidin/Biotin Blocking kit (Vector Laboratories) and CytoQ Background Buster (Innovex, Richmond, VA) following the manufacturer's protocols. Primary antibodies, rabbit anti-Ki67 (Novocastra Laboratories, Newcastle upon Tyne, United Kingdom) or rabbit anti -phospho-AKT:Ser 473 (Cell Signaling), were incubated overnight at 4jC in a humidified chamber. A biotinylated secondary antibody (goat antirabbit, Vector Laboratories) was visualized using R.T.U. Vectastain Elite ABC Reagent and 3,3 ¶-diaminobenzidine (Vector Laboratories). Alternatively, sections were examined for the presence of apoptotic cells by terminal deoxyribonucleotide transferase -mediated nick-end labeling (TUNEL) staining (Apoptag, Chemicon International, Temecula, CA). Following staining, sections were washed with H 2 O, counterstained with hematoxylin, dehydrated, and mounted. Observations were made on a Nikon Eclipse E800 system and images captured with ACT-1 software (Nikon Corporation, Melville, NY).
Results
Identification of potent selective inhibitors of ErbB ligand shedding. With the goal of discovering a single agent capable of inhibiting multiple ErbB pathways concomitantly, we set out to identify potent, selective, and well-tolerated inhibitors of a subset of the ADAM family of metalloproteases, herein called sheddases. Sheddases are responsible for the cleavage and activation of all three types of ErbB ligands: (a) those that bind solely to EGFR (e.g., TGF-a), (b) those that bind both EGFR and ErbB4 (e.g., HB-EGF), and (c) those that bind ErbB3 and/or ErbB4 (e.g., heregulin; reviewed in refs. 5, 22) . Importantly, the ultimate goal was to discover molecules with drug-like properties, including oral bioavailability and good pharmacokinetics. To this end, we synthesized a number of novel hydroxamic acid-derived metalloprotease inhibitors (18), 3 culminating in the identification of a series of molecules exemplified by INCB3619 (Fig. 1A) .
The sheddases-ADAMs responsible for processing the membrane-bound ErbB proligands-have been reported to include ADAM17 (also known as tumor necrosis factor-a converting enzyme) and ADAM10 (22 -29) . We thus established biochemical assays using recombinant proteins and fluorogenic peptide substrates and screened proprietary hydroxamic-based compounds (19) for inhibition of AD-AM10/ADAM17 enzyme activity. Hydroxamic acids have previously been shown to affect HB-EGF shedding through inhibition of an unknown enzyme (30) . Compounds from our collection that showed >50% inhibition of ADAM10 and/or ADAM17 at a concentration of 200 nmol/L were further characterized against a larger panel of metalloproteases and ADAM proteins to assess selectivity. A structure-activity relationship was established and provided direction for the synthesis or more potent and/or selective compounds. Using this strategy, INCB3619 was identified as a potent inhibitor of ADAM17 and ADAM10 activity with IC 50 values of 14 and 22 nmol/L, respectively. Moreover, INCB3619 shows excellent selectivity both within the ADAM family (e.g., IC 50 for ADAM9 is >5 Amol/L) and against a panel of MMPs (Table 1) . Functional cell-based assays confirmed the ability of INCB3619 to inhibit the shedding of TGF-a, HB-EGF, amphiregulin, and heregulin with nanomolar potencies (Fig. 1B) . Compounds that possess MMP activity but lack ADAM10/17 activity did not block ErbB ligand shedding in these assays (see below).
In addition to metalloprotease selectivity, multiple structural analogues were screened against a panel of >50 G-protein coupled receptors and ion channels (Cerep, Inc., ExpresSProfile) and no significant binding or inhibition was observed at 1 Amol/L (data not shown). Pharmacokinetic analysis of INCB3619 indicated that it was well-absorbed orally (10 mg/ kg but had a half-life of <2 h in the mouse). 5 As such, for in vivo administration, we took advantage of the excellent solubility of this compound and used implantable osmotic pumps. In larger species, such as dog, the half-life of INCB3619 was significantly longer (6.1 h). Improved pharmacokinetics in canine and nonhuman primates is a common feature of hydroxamic acidbased inhibitors. Therefore, continuous infusion in rodents is a better reflection of the predicted human pharmacokinetics and also serves to specifically test the therapeutic hypothesis by avoiding maximal drug exposures sufficient to potentially inhibit an array of MMPs nonspecifically.
In vitro and in vivo sequelae of selective ADAM inhibition. To begin to assess the biological effect of inhibiting ErbB ligand shedding, we first engineered a cellular model reliant on TGF-a expression for its transformed phenotype ( Fig. 2A) . NMuMG cells (immortalized mammary epithelial cells) were transduced with either an empty expression vector (NMuMG-V) or a vector encoding TGF-a (NMuMG-T). After confirming the ability of transfected cells to produce TGF-a, we tested the ability of INCB3619 to inhibit the shedding of TGF-a from the cell surface by analyzing tissue culture supernatants from cells grown in the presence or absence of compound (Fig. 2B) . In contrast to INCB3619, which inhibits ADAM10 and ADAM17, neither INCB8765 (ref. 9 ; an ADAM10 selective inhibitor; Fig. 2B , E) nor an inhibitor of MMPs that is both ADAM10 and ADAM17 sparing ( Fig. 2B, 4 ; ref. 9) inhibited TGF-a shedding. This agrees with the knockout data implicating ADAM17 as the enzyme responsible for TGF-a shedding (24, 31) . The ability to potently inhibit ErbB ligand cleavage was not specific to INCB3619 as additional compounds having similar enzymatic activities as INCB3619 were also able to do so (data not shown). Moreover, this pharmacology was not limited to cells of epithelial origin as nearly identical results were obtained using immortalized fibroblasts (Fig. 2C) . To extend these findings beyond contrived cell lines, we investigated the effect of sheddase inhibition on EGFR ligand release and cell proliferation in primary tumor cells surgically isolated from a consenting patient with squamous cell carcinoma of the buccal mucosa. This tumor type was chosen for investigation based on the clinical efficacy observed with antibodies that inhibit EGFR ligand binding. Using these cells, we show that INCB3619 can inhibit the release of amphiregulin (Fig. 2D ) in primary tumor cells in addition to ErbB ligands in established cell lines. Treatment with INCB3619 resulted in a significant decrease in proliferation of these primary tumor cells (Fig. 2E) . The EC 50 for proliferation was estimated to be near the EC 90 for amphiregulin shedding, suggesting that the ADAM sheddases may require marked inhibition for efficacy in this model system. Although the results in these primary cells are consistent with our cell line data, we cannot conclude that similar effects will be observed in all cancer cells. In contrast, in normal cells (human umbilical vascular endothelial cells or primary fibroblasts), there was no effect on proliferation at concentrations >10 times those effective on the tumor cells (data not shown).
Although these experiments show that selective sheddase inhibition can diminish the release of EGFR ligands from the cell surface, they do not show that this can affect EGFR signaling. To illustrate that inhibition of the release of TGF-a can reduce EGFR pathway activation, we treated the EGF-responsive A431 (Fig. 2F) . Similar experiments in which A431 cells were first incubated with an EGFR-neutralizing antibody showed no EGFR activation after addition of conditioned medium from NMuMG-T cells grown in the presence or absence of INCB3619 (data not shown), consistent with the conclusion that selective sheddase inhibition prevents activation of an autocrine TGF-a loop. Likewise, we have previously shown in multiple autonomous cell-based systems that pharmacologic or genetic inhibition of ADAM10/17 can inhibit ErbB receptor phosphorylation and downstream signaling (9) . However, as none of the cell lines studied here overexpress HER2, we did not detect significant changes to the amount of HER2 receptor phosphorylation (data not shown).
The ability of sheddase inhibition to reduce TGF-a shedding in vivo (Fig. 3A) as well as EGFR-driven tumor growth was investigated in both tumors of fibroblast ( Fig. 3B ; 42% TGI) and epithelial origin ( Fig. 3C ; 38% TGI). In agreement with data that has been generated using less selective compounds, the direct effect of sheddase inhibition addition on ex vivo cellular proliferation of established cell lines was not dramatic (refs. 32 -35; data not shown)-similar to what was observed by others using the C225 anti-EGFR antibody. This was not unexpected as any of a number of signaling pathways may be sufficient to drive proliferation in in vitro established ell culture systems and/or to activate the ErbB receptors via crosstalk among signaling pathways. However, three-dimensional tumor growth in vivo is different than growth in culture and ErbB signaling may play a more crucial role. Supporting this hypothesis, it has been shown that xenografts arising from cultured cells significantly up-regulate key players in ErbB signaling (36) . Therefore, evaluating the effect of sheddase inhibition in the more clinically relevant in vivo setting was imperative.
To determine if sheddase inhibition could be as efficacious as direct kinase inhibition using a low molecular weight TKI, such as gefitinib (Iressa), we treated mice bearing well established MCF-7 human breast cancer xenografts with either INCB3619 (60 mg/kg/d) or a maximally tolerated regimen of gefitinib (100 mg/kg/d) and concluded that both treatments resulted in equivalent tumor inhibition (50% and 48% TGI, respectively, and 19-day TGD for both; Fig. 4A ). Further, in support of the targeted nature of INCB3619 and gefitinib, neither agent showed efficacy against MDA-MB-231 xenografts, in which proliferation is driven, not by EGFR, but by mutated k-Ras (ref. 37 ; Fig. 4B and data not shown). In contrast, the nonselective MMP inhibitor marimastat, which inhibits both MMPs and sheddases (Fig. 1B) , was efficacious (60% TGI; Fig. 4B ), implying that the antitumor effect of marimastat is due to MMP inhibition and that INCB3619 is a selective compound and that its antitumor activity is not a result of its somewhat weak potency against MMP2. Indeed, a selective ADAM 10/17 inhibitor with 10-fold greater selectivity against MMP2 (INCB9725) retained its ability to inhibit tumor growth similarly to INCB3619 in the MDA-MB-435 tumor model (INCB3619: TGI, 35%; TGD, 10 days; INCB9725: TGI, 44%; TGD, 10 days; not shown).
As we and others have hypothesized that the antitumor effects obtained by inhibiting a single node of an ErbB pathway in isolation using one treatment modality may not be optimal, we investigated the potential of improving responses to an EGFR TKI by concomitantly treating with INCB3619. Mice with s.c. human non -small cell lung carcinoma xenografts were treated with gefitinib, INCB3619, or the combination and tumor growth was followed over a 2-week period (Fig. 4C) . As single agents, neither compound was efficacious; however, in combination, INCB3619 and gefitinib markedly inhibited tumor growth. Therapeutic benefit was obtained without notation of compounding toxicity. Similar results have been obtained using erlotinib in place of gefitinib (data not shown). These data are consistent with that recently published exemplifying the ability of INCB3619 to potentiate the effects of gefitinib in vitro (9) . Collectively, these data support that a sheddase inhibitor may be an efficacious and well-tolerated treatment modality for affecting ErbB pathways in cancer as a single agent or in combination with other targeted agents.
Because particular cancer types have been linked to elevated ErbB ligand expression, and hence increased EGFR activity (reviewed in ref. 38 ), we evaluated the activity of INCB3619 in a xenograft model of one such tumor type, head and neck squamous cell carcinoma. Subcutaneous tumors were established using the SCC4 cell line. As platinum-based therapeutic regimens are the standard of care for inoperable tumors of this type, we compared the efficacy of INCB3619 to the cytotoxic agent cisplatin, alone or in combination with INCB3619. INCB3619, as a single agent, nearly completely inhibited tumor growth during the treatment period (30% TGI) and subsequently resulted in a 13-day TGD (Fig. 5A) . In contrast, cisplatin was mostly ineffective (0% TGI and a 2-day TGD) although it was administered near its maximally tolerated dose (Fig. 5A and data not shown). Although cisplatin was lackluster as a single agent, the addition of INCB3619 was synergistic (66% TGI and a 24-day TGD), producing sporadic tumor regressions (in three of seven mice). Importantly, INCB3619 did not exacerbate the toxic effects of cisplatin, as assessed by animal weights and clinical observations (data not shown). To understand the Research.
on April 14, 2017. © 2007 American Association for Cancer clincancerres.aacrjournals.org Downloaded from mechanism behind the observed synergy, we analyzed similarly treated tumor samples ex vivo. Immunohistochemical analyses indicated that INCB3619 alone was sufficient to modestly decrease tumor cell proliferation nearly by nearly 10% (Fig. 5B,  top) and activation of the Akt/PKB survival signaling pathway (Fig. 5B, bottom) . This latter effect likely accounts for the increased responsiveness to the cytotoxic insult induced by treatment with cisplatin ( Fig. 5A and C) . However, even as a single agent, INCB3619 was sufficient to induce tumor cell apoptosis (Fig. 5C, top right) . Similar synergism was observed in a breast cancer xenograft model (MDA-MB-435) when INCB3619 was used in combination with paclitaxel, thus indicating that these effects were not particular to a specific tumor type or chemotherapeutic combination (paclitaxel, 10-day TGD; INCB3619, 20-day TGD; combination, 50-day TGD; Fig. 5D and E). INCB3619 also improved the therapeutic responses to other cytotoxic agents in models of pancreatic, non -small cell lung, and colon cancer (data not shown).
Although INCB3619 and related molecules are potent and highly selective, they are not completely devoid of MMP activity. For example, selectivity against MMP2 has proven difficult due to the similarity of its active site to those of ADAM10 and ADAM17. 6 As discussed above, although the efficacy of selective sheddase inhibitors do not require MMP2 activity, it is possible that inhibition of MMP2 has potential B, MDA-MB-231xenografts, which have a mutated K-ras and which are gefitinib insensitive, were treated with INCB3619 (y) or marimastat (4) (60 mg/kg/d) for 14 d, and tumor size was followed over time (n = 9). C, sheddase inhibition improves the therapeutic response to EGFR kinase inhibition.Well-established A549 non^small cell lung carcinoma tumor xenografts were treated for 14 d with vehicle (n), INCB3619 (4; 60 mg/kg/d), gefitinib (y; 100 mg/kg, bid), or a combination of the two agents (o). Tumors were measured twice weekly using calipers. Points, mean tumor volumes (n = 7/group); bars, SE. vertical arrows) , or a combination of the two agents (o), and tumor growth was followed over time (n = 7). B, tumors were harvested from similarly treated mice 8 h after the first dose of cisplatin and inhibition of cellular proliferation (Ki67, top) and survival signaling (p-Akt, bottom) was examined by immunohistochemistry (n = 4). C, apoptosis was also assessed usingTUNEL on these same samples (n = 4). Arrows, examples of apoptotic cells. D, INCB3619 also synergizes with taxanes in a human breast cancer xenograft model. S.c. well-established MDA-MB-435 tumors were treated with vehicle (n), INCB3619 (y; 60 mg/kg/d Â 14 d, horizontal arrow), paclitaxel (4;10 mg/kg, 2Â/wk Â 2, vertical arrows), or a combination of the two agents (o), and tumor growth was followed over time (n = 6/group). Points, mean tumor volumes; bars, SE. E, apoptosis was also assessed usingTUNEL on tumor samples collected 24 h after the first dose of taxane (n = 3). Arrows, examples of apoptotic cells. safety liabilities. For example, the clinical utility of broadspectrum MMP inhibitors has been hampered by unexpected musculoskeletal side effects. Because others have hypothesized that inhibition of sheddases may be responsible for this unwanted activity, we determined whether INCB3619 would induce these undesirable effects. To do so, we established a murine model of the MMP-induced musculoskeletal side effects similar to that described previously in the rat (21) . Mice were treated with INCB3619 or the broad-spectrum MMP inhibitor marimastat at doses significantly higher than those required for efficacy in xenograft models. After 14 days of continuous treatment, mice were sacrificed and their knee joints were analyzed. Marimastat treatment clearly induced joint fibroplasia, whereas administration of a selective sheddase inhibitor did not ( Fig. 6A and B) . Of note, de novo angiogenesis was also observed in the marimastat-treated mice in the area of fibrosis. Similar steady-state drug exposures were achieved for both compounds (INCB3619, 691 F 228 nmol/L; marimastat, 448 F 74 nmol/L). Thus, sheddase inhibition can be shown to be both efficacious and devoid of the toxicity that prevented the exploration of this mechanism in earlier clinical trials with drugs such as marimastat. In addition, INCB3619 is somewhat active against MMP12, and studies in knockout mice have suggested a potential role for MMP12 in the vascularization of murine lung tumor metastasis via the reduced formation of angiostatin-a reported endogenous angiogenesis inhibitor and substrate of MMP12 (39) . The role of such molecules in the human condition, however, is a point of contention. Indeed, recent clinical data supports a beneficial role of MMP12 inhibition in non -small cell lung carcinoma, in which MMP12 expression correlates with metastasis while inversely correlating with relapse-free survival (40) . Taken together, these data suggest that the selective sheddase inhibitors, such as INCB3619, are capable of preventing the functional activation of ErbB ligands and have therapeutic potential both as single agents and when used in combination with additional therapeutics. Furthermore, these compounds are extremely well tolerated in xenograft experiments and do not exacerbate the toxicities of cytotoxic therapies. In addition, we evaluated toxicologic variables indicative of hematologic, renal, and hepatic dysfunction and found no significant effect in rodents after continuous administration of INCB3619 at a dose significantly greater than that required for efficacy (Table 2) . Moreover, untransformed cells (e.g., human umbilical vascular endothelial cells or primary fibroblasts) were resistant to the growth-inhibitory effects of INCB3619 at concentrations 10 times higher than those effective in transformed cells. 7 These findings suggest selective ADAM10/17 inhibitors, such as INCB3619, have the potential to effect tumor growth and survival while being better tolerated than the broad-spectrum MMP inhibitors.
Discussion
Targeted therapies for the treatment of cancer have advanced significantly in recent years and continue to show great promise. The challenges that the medical and scientific communities now face involve the identification of populations that will derive clinical benefit from these agents and the delineation of an optimal strategy for combining these agents with current cytotoxic regimens to improve response rates while decreasing exposure to unnecessary side effects. Nonetheless, significant advances are rapidly being made. For example, the identification of the mechanism(s) of resistance to some of these new therapies, such as imatinib (41 -43) and the EGFRselective TKIs (14, 15) , has occurred within a short time after these agents were introduced as approved therapies. As such, complementary or alternative therapies are actively being pursued. Our identification of potent, selective inhibitors of the ErbB ligand sheddases that are efficacious, well tolerated, and have suitable drug-like properties represents a new opportunity to affect clearly validated oncology targets. These molecules prevent the release of ligands for multiple ErbB family members representing a new class of pan-ErbB inhibitors.
There is strong evidence that ligand shedding is critical for the transforming potential of EGFR (reviewed in ref. 44 ) and increased ErbB ligand expression is a common event in human cancers (38) . This latter observation my be explained, in part, by observations demonstrating metalloprotease-dependent ErbB ligand shedding is increased upon activation of a number of diverse signaling pathways linked to human cancers (e.g., WNT, prostaglandin E2, and LPA; refs. 3, 5, 22, 23) . Further, correlative clinical and preclinical data suggest that ErbB pathways may compensate for one another, thus Fig. 6 . Selective sheddase inhibition does not cause the musculoskeletal side effects associated with broad-spectrum MMP inhibition. A, mice were treated with INCB3619 or the broad-spectrum MMP inhibitor marimastat (60 mg/kg/d) for 14d. Knee joints were isolated and examined for histopathology. Arrow, fibrosis; arrowhead, angiogenesis; s, synovium; m, meniscus; c, cartilage. B, the extent of knee joint fibrosis was quantified by blinded scoring on a scale of 0 (no fibrosis) to 4 (severe fibrosis; n = 4).
providing a potential mechanism of ''resistance'' to selective ErbB-targeted therapies. Although this observation has yet to be conclusively proven, it suggests that sheddase inhibitors should synergize with TKIs (or other targeted therapies) because they inhibit unique aspects of a common pathway. Our studies demonstrating that INCB3619 enhances gefitinib sensitivity ( Fig. 4C; ref. 9 ) support this concept and may represent a well-tolerated alternative to combining EGFR TKIs with antibodies specific solely for the EGFR and its ligands. Clearly, the understanding of intrinsic sensitivity to ErbB inhibition in the clinic remains an evolving field. Although EGFR amplification and/or mutation may affect response rates, multiple mechanisms that affect sensitivity may exist either in parallel or in series.
Selective sheddase inhibition seems to be well tolerated and can be equally efficacious as a TKI administered at a maximally tolerated dose. The mechanism of this apparent differential tolerability is an active area of study; however, clearly, inhibiting ligand-stimulated receptor activation is different than inhibiting basal kinase activity through direct kinase inhibition. For example, ligand-independent activation of ErbB receptors, as has been observed upon integrinmediated binding to extracellular matrix, is unlikely to be perturbed by sheddase inhibition (45) . Alternatively, a number of reports have shown that expression of tissue inhibitor of metalloproteinase-3 (TIMP-3), a gene encoding for an endogenous sheddase inhibitor, is often silenced in solid tumors, via promoter methylation (46 -48) . TIMP-3, as opposed to TIMP-1, TIMP-2, and TIMP-4, is the only endogenous inhibitor known to inhibit both ADAM10 and ADAM17 (ref. 49 and references therein) and may, therefore, regulate basal levels of ErbB ligand production. Perhaps, selective sheddase inhibitors have been so well tolerated because they merely complement or compensate for a loss of TIMP-3 activity in a pathologic setting.
Although INCB3619 and related molecules are zinc-dependent metalloprotease inhibitors, they are highly selective against a broad panel of MMPs and thus do not share their musculoskeletal side effects. In addition, unlike broadspectrum MMP inhibitors, the sheddase-selective compounds do not show efficacy in a xenograft model, which has a mutated K-ras , and do not show efficacy in in vitro angiogenesis systems (i.e., inhibition of human umbilical vascular endothelial cell proliferation, migration, invasion, and tube formation; data not shown), further distinguishing their mechanism of tumor growth inhibition from that of MMP inhibitors. It remains unclear why this latter class of agents failed in the clinic but it is intriguing to find that some MMP activities have been linked to the generation of antiangiogenic molecules (e.g., endostatin and tumstatin; ref. 50) . It is therefore tempting to speculate that the effect of these antiangiogenic products of MMP activity may be greater in human cancer than in the mouse or that in the preclinical mouse models, the concentration of MMP inhibitors was high enough to affect the sheddases, thus partly explaining their efficacy against some tumor xenografts.
In this report, we have shown that selective sheddase inhibitors can prevent the release of ErbB ligands from cell lines and primary patient tumor cells and that this can result in inhibition of ErbB signaling pathways in vitro and in vivo. Although we cannot conclude that inhibition of sheddases in addition to ADAM10 and ADAM17 can be important for this activity (e.g., ADAM12 or ADAM15), we have clearly shown that MMP sparing protease inhibition is sufficient for efficacy. Moreover, our previous in vitro studies have shown that selective genetic (RNA interference) inhibition of ADAM17 and not ADAM9 or ADAM15 is sufficient to affect ErbB signaling pathways (9) . These molecules thus have antitumor activity in tumor models reported to be sensitive to perturbations in ErbB pathways, but not elsewhere (e.g., MDA-MB-231 tumors). Although sheddase inhibitors do possess significant single-agent antitumor activity, their ability to inhibit survival pathways such as Akt and our preclinical findings demonstrating additive or synergistic effects support the use of combination therapy in the clinic. This is further substantiated by their excellent tolerability and their lack of exacerbating the toxicity associated with standard chemotherapeutics or targeted agents. Further, combining sheddase inhibitors with other ErbB inhibitors may thwart multiple mechanisms of resistance, such as kinase (gatekeeper) mutations or increased ligand expression. As such, selective sheddase inhibitors may complement the existing arsenal of anticancer agents; hence, clinical investigation of sheddase inhibition is undoubtedly warranted. 
